Telomir Pharmaceuticals Reports $1.7M Net Loss and Merger Completion in Latest 10-Q Filing

Telomir Pharmaceuticals, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company, which is focused on developing small-molecule therapeutics for cancer treatment, recorded no revenue during the quarter. However, it reported a net loss of $1.7 million, a notable decrease from the $5.1 million loss reported in the same quarter of the previous year. For the six months ending June 30, 2026, the net loss was $2.7 million, down from $7.3 million in the prior year, indicating a reduction in operating costs.

The company’s operating costs for the three months ended June 30, 2026, totaled $1.8 million, a decrease of $3.3 million compared to the same period in 2025. This reduction was primarily driven by a significant drop in general and administrative expenses, which fell from $5.0 million to $1.3 million, largely due to decreased stock-based compensation. Research and development expenses increased to $444,674 from $42,839, reflecting heightened activity related to the advancement of its lead candidate, Telomir-Zn.

A key strategic development for Telomir was the completion of its merger with TELI Pharmaceuticals on April 22, 2026. This merger allowed Telomir to consolidate its rights to Telomir-Zn, which is currently under FDA review for clinical trials in patients with advanced triple-negative breast cancer. As part of the merger, Telomir issued 34,389,710 shares of common stock to TELI shareholders, resulting in a deemed dividend of $46.1 million, which was recorded as a reduction in income available to shareholders.

Operationally, Telomir's cash position as of June 30, 2026, stood at approximately $5.2 million, down from $7.3 million at the end of 2025. The company utilized about $2.8 million in cash for operations during the first half of 2026. The merger with TELI also included a $1 million cash contribution from Bayshore Trust, a related party, which is expected to support ongoing development efforts. Looking ahead, Telomir anticipates needing additional funding to support its clinical trials and operational expenses, as it has not yet generated revenue from product sales.

In summary, Telomir Pharmaceuticals is navigating a critical phase in its development with a focus on advancing its lead therapeutic candidate while managing its financial resources effectively. The company is actively seeking additional funding to ensure it can continue its operations and clinical development programs in the coming months.